Hypothesis

Aging induces occludin downregulation in the small intestine, which triggers a compensatory increase in claudin‑2‑mediated paracellular water flux. The resulting luminal hypotonicity reshapes the microbiota toward taxa that produce fewer endocannabinoid precursors, thereby reducing CB1 receptor signaling. Diminished CB1 activity exacerbates ZO‑1 loss via the miR‑191‑5p/NF‑κB axis, while occludin remains low because its restoration depends on microbiota‑derived signals that are now deficient. This creates a self‑reinforcing loop that tightens barrier dysfunction and fuels systemic inflammaging via LPS‑TLR4 signaling.

Rationale

• ’s work shows CB1‑driven ZO‑1 loss and microbiota‑driven occludin regulation are non‑redundant pathways [CB1 receptor downregulation in aging specifically drives ZO‑1 loss through increased miR‑191-5p and NF-κB activation]; [microbiota shifts independently regulate both ZO-1 and occludin, as demonstrated by young microbiota transplantation restoring both proteins]
• Claudin‑2 forms water‑selective channels; its upregulation is known to increase intestinal permeability to solutes and water [[PMID: 29563255]]
• Microbiota composition influences intestinal endocannabinoid tone; specific bacterial strains modulate N‑acylethanolamide levels [[PMID: 31118456]]
• Sex‑stratified immune responses noted in the microbiota transplant study suggest hormonal modulation of miR‑191‑5p expression [microbiota shifts independently regulate both ZO-1 and occludin, as demonstrated by young microbiota transplantation restoring both proteins]

Novel Mechanistic Insight

1. Occludin loss → claudin‑2 up‑regulation: Loss of occludin destabilizes the tight junction strand, prompting a homeostatic rise in claudin‑2 to preserve basal permeability to ions.
2. Claudin‑2‑mediated water flux → luminal hypotonicity: Increased water secretion lowers osmolarity, favoring bacterial strains that thrive in low‑osmolarity niches and that produce fewer endocannabinoid‑precursor lipids.
3. Microbiota‑derived endocannabinoid decline → CB1 signaling drop: Reduced luminal endocannabinoids decrease CB1 activation on enterocytes, lifting repression of miR‑191‑5p and permitting NF‑κB‑driven ZO‑1 transcription suppression.
4. ZO‑1 loss amplifies barrier leak: Combined ZO‑1 and occludin deficits increase macromolecular permeability, allowing LPS translocation that drives TLR4‑mediated inflammaging [Gut permeability loss allows LPS translocation that drives TLR4 activation, immune dysregulation, and thymic involution]
5. Sex differences: Estrogen suppresses miR‑191‑5p transcription; thus females exhibit a blunted ZO‑1 response to CB1 loss but remain vulnerable to microbiota‑dependent occludin regulation, predicting divergent susceptibility.

Testable Predictions

• Prediction 1: In aged mice, claudin‑2 protein and mRNA will be elevated in the small intestine concomitant with reduced occludin, and this rise will correlate with increased fecal water content.
• Prediction 2: Pharmacologic inhibition of claudin‑2 (e.g., with claudin‑2‑specific siRNA or a blocking peptide) will normalize luminal osmolarity, restore a youth‑like microbiota endocannabinoid profile, and rescue CB1 signaling without directly altering occludin levels.
• Prediction 3: Germ‑free aged mice colonized with microbiota from young donors supplemented with endocannabinoid‑producing bacteria (e.g., Lactobacillus spp. that generate N‑palmitoylethanolamide) will prevent the decline in CB1 activity and attenuate ZO‑1 loss, even when claudin‑2 remains high.
• Prediction 4: Female aged mice will show a smaller reduction in ZO‑1 after CB1 antagonism compared with males, but a comparable occludin deficit after microbiota depletion, reflecting sex‑specific regulation.

Experimental Approach

1. Measure claudin‑2: Western blot and qPCR on isolated intestinal epithelium from young (3 mo) and aged (24 mo) male and female mice; assay fecal water content via gravimetric analysis.
2. Manipulate claudin‑2: Deliver claudin‑2‑specific siRNA via oral nanoparticle to aged mice; assess osmolarity (fecal supernatant osmolality), microbiota metabolomics (targeted LC‑MS for endocannabinoids), CB1 receptor activity (GTPγS binding), and ZO‑1/occludin immunofluorescence.
3. Microbiota rescue: Colonize antibiotic‑treated aged mice with defined consortia: (a) young microbiota alone, (b) young microbiota + engineered L. plantarum overexpressing anandamide synthase; evaluate CB1 signaling, ZO‑1 levels, and serum LPS/TLR4 cytokines.
4. Sex‑specific assays: Repeat CB1 antagonism (AM251) and microbiota depletion (cocktail antibiotics) in both sexes; quantify ZO‑1 and occludin by immunoblot and confocal microscopy; analyze miR‑191‑5p expression via RT‑qPCR.
5. Functional read‑out: Perform FITC‑dextran permeability assay and measure systemic inflammaging markers (serum IL‑6, TNF‑α, thymic histology).

Falsifiability

If claudin‑2 inhibition fails to alter luminal osmolarity, microbiota endocannabinoid levels, or CB1 signaling, or if microbiota‑derived endocannabinoid supplementation does not rescue ZO‑1 despite persistent claudin‑2 elevation, the proposed feed‑forward loop is refuted. Similarly, absence of sex‑dependent differences in ZO‑1 versus occludin responses would invalidate the hormonal modulation component.

Implications

Confirming this mechanism would identify claudin‑2 as a novel upstream regulator of the CB1‑miR‑191‑5p‑ZO‑1 axis and suggest that tightening water‑channel activity—rather than merely boosting TJ protein expression—could break the cycle of barrier failure and inflammaging in aging.